Drugs Likely to Launch 2026–2030
How to forecast launches without falling for analyst hype.
A decision-grade approach to identifying which assets are actually likely to launch by 2030 — using PoS, regulatory and commercial-readiness signals.
"Which 2026–2030 launches will materially shift the value pool in our TA?"
Of all currently-tracked Phase 2/3 assets, fewer than 30% will reach approval and launch by 2030. The right view applies PoS, timeline and pricing realism to the launch list.
“Drugs likely to launch by 2030” is the single most cited and least defensible analyst output in pharma. Most published lists count Phase 3 assets and call it done. The right view applies attrition, timeline risk and commercial readiness simultaneously.
Three multiplicative haircuts
(1) PoS by TA × modality × sponsor. (2) Timeline risk: recruitment, regulatory, manufacturing. (3) Commercial readiness: payer prep, manufacturing capacity, sales infrastructure. Multiply them — the launch list compresses by 60–70%.
Sequence the survivors by geography
The launch year for the same asset can vary 18+ months across US/EU/JP/CN. A defensible launch view forecasts country-by-country, not “global by 2028.”
What we’re seeing in the data.
<30% of late-stage launch on time
Cumulative attrition + delays compress headline launch lists materially.
Onc and rare disease lead launch volume
Faster pathways and smaller trials accelerate approvals in these TAs.
Modality matters for timing
ATMPs face longer manufacturing-led delays than small molecules.
Regional approval lag
US/EU first; APAC follow at 6–24 months — adjust forecasts geo-by-geo.
How to think about it.
-
01
Build the candidate list
P2b/P3/registrational from credible sponsors.
-
02
Apply PoS and timeline
TA-, sponsor-, endpoint-adjusted.
-
03
Score commercial readiness
Manufacturing, payer prep, KOL engagement.
-
04
Forecast peak revenue
TAM × share × pricing × LoE.
-
05
Sequence by geography
US/EU first, JP/CN/EM follow.
What separates a good answer from a defensible one.
ATMP manufacturing capacity is a recurring delay driver.
Negative AdComm can push launches by 12+ months.
HTA timelines often shift effective launch by 3–9 months.
Combination launches depend on partner asset success.
Where the signal comes from.
Common questions.
Why do most launch lists overstate?
They count P3 assets without applying PoS, timeline and commercial readiness — three multiplicative haircuts.
How fresh should this list be?
Quarterly at minimum; monthly during high-readout cadence quarters.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist